Standalone Q4 revenue has shown a growth of 19 per cent and PAT growth of 20 per cent
Ajanta Pharma has posted its performance for the fourth quarter and year ended March 31, 2015. The Q4 FY ’15 standalone results show that revenue from operations grew 19 per cent at Rs 369 crore against Rs 311 crore. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew 25 per cent at Rs 141 crore against Rs 112 crore and EBITDA was 38 per cent of the revenue. Profit before tax (before exceptional item) grew 35 per cent at Rs 130 crore against Rs 97 crore. Profit after exceptional items and tax grew 20 per cent at Rs 84 crore against Rs 70 crore and PAT was at Rs 73 crore of revenue. Exports contributed 67 per cent of the revenue for the quarter.
The 12-month standalone results show that revenue from operations grew 22 per cent at Rs 1,356 crore, against Rs 1,110 crore. EBITDA was 37 per cent at Rs 473 crore against Rs 346 crore, and the EBITDA was at 35 per cent of revenue. Profit before tax (before exceptional item) grew 44 per cent at Rs 452 crore against Rs 313 crore. Profit after exceptional items and tax grew 39 per cent at Rs 306 crore against Rs 221 crore, PAT at 23 per cent of revenue. Exports contributed 63 per cent of the total operating income.
The 12 months consolidated financial performance reveals that revenue from operations grew 23 per cent at Rs 1,481 crore against Rs 1,208 crore. EBITDA was 37 per cent at Rs 505 crore against Rs 369 crore, EBITDA at 34 per cent of revenue. Profit before tax (before exceptional item) grew 41 per cent at Rs 464crore against Rs 330 crore. Profit after exceptional item and tax grew 32 per cent at Rs 310 crore against Rs 234 crore and PAT at 21 per cent of revenue. Exports contributed 66 per cent of the total operating income.
Yogesh M Agrawal, Managing Director, Ajanta Pharma said, “All our businesses continue to perform in-tine with our expectations. We remain committed and focused on existing geographies and therapeutic segments to drive above industry growth consistently. We continue to take proactive steps and make right investments in infrastructure – manufacturing and R&D – at the right time. “